{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:05:56Z","timestamp":1791223556513,"version":"4.1.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,11]]},"DOI":"10.1097\/qad.0b013e3281ac229b","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T04:04:06Z","timestamp":1182485046000},"page":"1405-1414","source":"Crossref","is-referenced-by-count":67,"title":["Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase"],"prefix":"10.1097","volume":"21","author":[{"given":"Urvi M","family":"Parikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Zelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sluis-Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1054-3589(00)49024-1","article-title":"Inhibitors of HIV-1 reverse transcriptase","volume":"49","author":"Parniak","year":"2000","journal-title":"Adv Pharmacol"},{"key":"R2-3-20210130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1007\/PL00000626","article-title":"Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)","volume":"57","author":"Sluis-Cremer","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"R3-3-20210130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/135965350300800209","article-title":"Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues","volume":"8","author":"Selmi","year":"2003","journal-title":"Antivir Ther"},{"key":"R4-3-20210130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2174\/1389200043335478","article-title":"Structural determinants and molecular mechanisms for the resistance of HIV-1 RT to nucleoside analogues","volume":"5","author":"Deval","year":"2004","journal-title":"Curr Drug Metab"},{"key":"R5-3-20210130","doi-asserted-by":"crossref","first-page":"15908","DOI":"10.1021\/bi981200e","article-title":"Phenotypic mechanism of HIV-1 resistance to 3\u2032-azido-3\u2032-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase","volume":"37","author":"Arion","year":"1998","journal-title":"Biochemistry"},{"key":"R6-3-20210130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1097-2765(00)80185-9","article-title":"A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase","volume":"4","author":"Meyer","year":"1999","journal-title":"Mol Cell"},{"key":"R7-3-20210130","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1128\/JVI.75.10.4832-4842.2001","article-title":"Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase","volume":"75","author":"Boyer","year":"2001","journal-title":"J Virol"},{"key":"R8-3-20210130","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1021\/bi990709m","article-title":"Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase","volume":"38","author":"Feng","year":"1999","journal-title":"Biochemistry"},{"key":"R9-3-20210130","doi-asserted-by":"crossref","first-page":"48466","DOI":"10.1074\/jbc.M107003200","article-title":"Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue","volume":"276","author":"Selmi","year":"2001","journal-title":"J Biol Chem"},{"key":"R10-3-20210130","doi-asserted-by":"crossref","first-page":"42097","DOI":"10.1074\/jbc.M206725200","article-title":"The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues","volume":"277","author":"Deval","year":"2002","journal-title":"J Biol Chem"},{"key":"R11-3-20210130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1074\/jbc.M308806200","article-title":"Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations","volume":"279","author":"Deval","year":"2004","journal-title":"J Biol Chem"},{"key":"R12-3-20210130","doi-asserted-by":"crossref","first-page":"25489","DOI":"10.1074\/jbc.M313534200","article-title":"A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions","volume":"279","author":"Deval","year":"2004","journal-title":"J Biol Chem"},{"key":"R13-3-20210130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/135965350100600205","article-title":"Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication","volume":"6","author":"Naeger","year":"2001","journal-title":"Antivir Ther"},{"key":"R14-3-20210130","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1128\/JVI.76.7.3248-3256.2002","article-title":"The M184V mutation reduces the selective excision of zidovudine 5\u2032-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1","volume":"76","author":"Boyer","year":"2002","journal-title":"J Virol"},{"key":"R15-3-20210130","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1128\/AAC.49.7.2648-2656.2005","article-title":"The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations","volume":"49","author":"Miranda","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-3-20210130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/135965350601100209","article-title":"The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations","volume":"11","author":"White","year":"2006","journal-title":"Antivir Ther"},{"key":"R17-3-20210130","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT\u20133TC combination therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"R18-3-20210130","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/infdis\/169.4.722","article-title":"Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations","volume":"169","author":"Shafer","year":"1994","journal-title":"J Infect Dis"},{"key":"R19-3-20210130","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1128\/AAC.46.12.4000-4003.2002","article-title":"Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine","volume":"46","author":"Stoeckli","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-3-20210130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1128\/AAC.49.3.1139-1144.2005","article-title":"In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase","volume":"49","author":"Parikh","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-3-20210130","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1097\/00002030-200210180-00018","article-title":"The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients","volume":"16","author":"Winston","year":"2002","journal-title":"AIDS"},{"key":"R22-3-20210130","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/JVI.80.10.4971-4977.2006","article-title":"The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations","volume":"80","author":"Parikh","year":"2006","journal-title":"J Virol"},{"key":"R23-3-20210130","first-page":"22","article-title":"K65R, TAMs and tenofovir","volume":"6","author":"Miller","year":"2004","journal-title":"AIDS Rev"},{"key":"R24-3-20210130","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1097\/00002030-200410210-00018","article-title":"Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations","volume":"18","author":"Valer","year":"2004","journal-title":"AIDS"},{"key":"R25-3-20210130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00126334-200501010-00019","article-title":"Prevalence and conditions of selection of the K65R mutation in the reverse transcriptase gene of HIV-1","volume":"38","author":"Segondy","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-3-20210130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/jmv.20359","article-title":"Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients","volume":"76","author":"Wirden","year":"2005","journal-title":"J Med Virol"},{"key":"R27-3-20210130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1086\/505711","article-title":"Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level","volume":"194","author":"Parikh","year":"2006","journal-title":"J Infect Dis"},{"key":"R28-3-20210130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1432-1033.1990.tb15306.x","article-title":"Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography","volume":"187","author":"Le Grice","year":"1990","journal-title":"Eur J Biochem"},{"key":"R29-3-20210130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0076-6879(95)62015-X","article-title":"Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase","volume":"262","author":"Le Grice","year":"1995","journal-title":"Methods Enzymol"},{"key":"R30-3-20210130","doi-asserted-by":"crossref","first-page":"25988","DOI":"10.1016\/S0021-9258(18)35706-5","article-title":"Mechanism and fidelity of HIV reverse transcriptase","volume":"267","author":"Kati","year":"1992","journal-title":"J Biol Chem"},{"key":"R31-3-20210130","doi-asserted-by":"crossref","first-page":"29047","DOI":"10.1074\/jbc.M503166200","article-title":"The 3\u2032-azido group is not the primary determinant of 3\u2032-azido-3\u2032-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1","volume":"280","author":"Sluis-Cremer","year":"2005","journal-title":"J Biol Chem"},{"key":"R32-3-20210130","doi-asserted-by":"crossref","first-page":"9251","DOI":"10.1074\/jbc.275.13.9251","article-title":"Mechanism by which phosphonoformic acid resistance mutations restore 3\u2032-azido-3\u2032-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase","volume":"275","author":"Arion","year":"2000","journal-title":"J Biol Chem"},{"key":"R34-3-20210130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0076-6879(95)49030-2","article-title":"Rapid quench kinetic analysis of polymerases, adenosinetriphosphatases, and enzyme intermediates","volume":"249","author":"Johnson","year":"1995","journal-title":"Methods Enzymol"},{"key":"R35-3-20210130","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J Infect Dis"},{"key":"R36-3-20210130","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1097\/01.aids.0000189851.21441.f1","article-title":"A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT","volume":"19","author":"White","year":"2005","journal-title":"AIDS"},{"key":"R37-3-20210130","doi-asserted-by":"crossref","first-page":"8831","DOI":"10.1021\/bi034435l","article-title":"Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis","volume":"42","author":"Ray","year":"2003","journal-title":"Biochemistry"},{"key":"R38-3-20210130","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1128\/JVI.74.8.3579-3585.2000","article-title":"The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis","volume":"74","author":"Gotte","year":"2000","journal-title":"J Virol"},{"key":"R39-3-20210130","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1128\/AAC.49.7.2657-2664.2005","article-title":"Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase","volume":"49","author":"Frankel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-3-20210130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nsmb760","article-title":"Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir","volume":"11","author":"Tuske","year":"2004","journal-title":"Nat Struct Mol Biol"},{"key":"R41-3-20210130","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1126\/science.282.5394.1669","article-title":"Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance","volume":"282","author":"Huang","year":"1998","journal-title":"Science"},{"key":"R42-3-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/bj3480077","article-title":"Mutational analysis of Lys65 of HIV-1 reverse transcriptase","volume":"348","author":"Sluis-Cremer","year":"2000","journal-title":"Biochem J"},{"key":"R43-3-20210130","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1128\/JVI.72.6.5093-5098.1998","article-title":"A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine","volume":"72","author":"Kemp","year":"1998","journal-title":"J Virol"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200707110-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:48:00Z","timestamp":1786034880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200707110-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3281ac229b","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,11]]}}}